Brian Maguire

April 12, 2021

Brussels-based journalist, producer, broadcaster, and events moderator, Brian Maguire, hosts live radio and television debates with European Commissioners, Ambassadors, Members of the European Parliament and independent experts. A EURONEWS and Irish television contributor, he also presents the EURACTIV digital technology series ‘The Presidency’ and the political interview series ‘Over A Coffee’. He specialises in European politics and business, producing short documentary films and news reports exploring Europe’s competing policy dimensions, including the digital economy, the Green Deal, human rights, and the rule of law. A graduate in Government and Law, he is currently completing a Master in Laws pecializing in Tech, Media and Telecoms, at the Centre for Commercial Law Studies (CCLS), Queen Mary University of London, in Paris.

How Europe Lost Global Biopharmaceutical R&D Leadership to the United States: Lessons for Today

September 9, 2025

By Anne Prichett Today, the United States leads the world in biopharmaceutical industry research and development (R&D), supporting nearly five million jobs and generating more than $1.65 trillion in economic output. This position of global leadership, however, is relatively recent. Until the late 1980s, Europe–particularly Germany, France,

If Private Sector R&D Is the Future, IP Policy Must Catch Up

September 8, 2025

By Chris Borges The President’s Budget Request for fiscal year 2026 (FY 2026) includes steep cuts to federal research and development (R&D) funding—a troubling signal for U.S. innovation and economic security. While congressional committees may push back on the most severe reductions, the signs are clear: Federal R&D funding is likely

Don’t Tax Invention: The Risks of a Patent Tax

September 4, 2025

By Sujai Shivakumar and Chris Borges The Commerce Department is reportedly considering a novel revenue-raising idea to address the national debt: a “patent tax.” Under this proposal, patent holders would be required to pay the federal government between 1 and 5 percent of their patents’ assessed value each year. While the